Zentalis Pharmaceuticals Files 8-K
Ticker: ZNTL · Form: 8-K · Filed: May 20, 2025 · CIK: 1725160
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Zentalis filed an 8-K on 5/20/25 for Reg FD and exhibits.
AI Summary
On May 20, 2025, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Zentalis Pharmaceuticals is providing updates and required financial information to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain any negative news or significant events.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- May 20, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Zentalis Pharmaceuticals?
The primary purpose is for Regulation FD Disclosure and to file Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is May 20, 2025.
What is the state of incorporation for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals is incorporated in Delaware.
What is the Standard Industrial Classification code for Zentalis Pharmaceuticals?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What were Zentalis Pharmaceuticals' former names?
Zentalis Pharmaceuticals was formerly known as Zentalis Pharmaceuticals, LLC (since 20200107) and Zeno Pharma, LLC (since 20171212).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding Zentalis Pharmaceuticals, Inc. (ZNTL).